ETrade Capital Management’s CervoMed CRVO Stock Holding History

ETrade Capital Management’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-146	Closed	-$11K	–	897
2020 Q2	$11K	Buy	+146	New	+$8.88K	﹤0.01%	839

Other funds holding CRVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

ETrade Capital Management's CRVO Position: Q3 2020 in Review

ETrade Capital Management sold out of CervoMed (CRVO) in Q3 2020, closing a stake of 146 shares — an estimated $11K sold.

ETrade Capital Management first reported a position in CRVO in Q2 2020 and held it in 1 quarter. The position peaked at $11K in Q2 2020. 22 funds tracked by Wall St. Rank hold CRVO as of Q3 2020.

ETrade Capital Management reported no remaining CervoMed position as of Q3 2020 after selling out during the quarter.
ETrade Capital Management sold 146 CervoMed shares in Q3 2020, an estimated $11K.
ETrade Capital Management first reported a position in CervoMed in Q2 2020 and held it in 1 quarter.
ETrade Capital Management's CervoMed position peaked at $11K in Q2 2020.
22 funds tracked by Wall St. Rank held CervoMed as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.